ISSN:
1432-0584
Keywords:
Low-dose aclarubicin
;
Essential thrombocythemia
;
Blastic transformation
;
Myelofibrosis
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary We attempted treatment with low-dose aclarubicin (ACR), a new anthracycline, in a 66-year-old man with blastic transformation of essential thrombocythemia (ET). Two courses of ACR (20 mg/day x 7 days) were given intravenously. He showed a good response to this therapy without severe side effects. He has since maintained a state of prolonged remission. These observations indicate that low-dose ACR may be beneficial for management of the blastic transformation of ET.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF01703149
Permalink